In a randomized clinical trial of antibiotic treatments for community-acquired pneumonia (CAP), researchers did not find that monotherapy with β-lactam alone was worse than a combination therapy with a macrolide in patients hospitalized with moderately severe pneumonia, write author Nicolas Garin, M.D., Hôpital Riviera-Chablais, Switzerland, and colleagues.
CAP is responsible for a high burden of deaths, hospitalizations and health care costs. International medical societies differ in their recommendations on how to treat it. North American guidelines recommend treatment of atypical pathogens with respiratory antibiotics or with a combination of a macrolide and a β-lactam for all hospitalized patients. European guidelines recommend combination therapy only for more severely ill patients. The authors sought to determine whether monotherapy with β-lactam alone was noninferior (not worse than) to a combination therapy with a macrolide for patients in the hospital with moderately severe pneumonia.
The randomized trial included 580 patients (291 received monotherapy and 289 had combination therapy). The median age of patients was 76 years.
After seven days of treatment, 120 of 291 patients (41.2 percent) who received monotherapy vs. 97 of 289 (33.6 percent) who had combination therapy had not reached clinical stability. Patients who were infected with atypical pathogens or with more severe pneumonia were less likely to reach clinical stability with monotherapy. Patients not infected with atypical pathogens or with less severity of illness had equivalent outcomes in the two treatment groups. There were more 30-day readmissions in the monotherapy treatment group (7.9 percent vs. 3.1 percent). Mortality, admission to the intensive care unit, complications, length of stay and pneumonia recurrence did not differ between the two groups within 90 days.
"We were unable to demonstrate noninferiority of initial empirical treatment with a β-lactam agent alone in hospitalized patients with moderately severe community-acquired pneumonia. There was a nonsignificant trend toward superiority of combination therapy, which could represent a chance finding or true superiority that was not significant because of insufficient power."
In a related commentary, Jonathan S. Lee, M.D., and Michael J. Fine, M.D., M.Sc., of the University of Pittsburgh School of Medicine, write: "We believe that evidence from this trial pushes the pendulum further in favor of antibiotic therapy covering atypical and typical bacterial pathogens for patients hospitalized for CAP. Lessons learned from its design and results should inform future trials required to definitively settle this debate. ... Finally, to maximize the detection of atypical pathogens and ensure their timely treatment in all study arms, future trials should use the most comprehensive point-of-care diagnostic testing for pneumonia pathogens. Although trials with these features would bring us substantially closer to ending the debate, until that time, dual therapy should remain the recommended treatment for patients hospitalized for CAP. "
Explore further: Outcomes for older adults with pneumonia who receive treatment including azithromycin
More information: JAMA Intern Med. Published online October 6, 2014. DOI: 10.1001/jamainternmed.2014.4887
Commentary: Debate on Antibiotic Therapy for Patients Hospitalized for Pneumonia, JAMA Intern Med. Published online October 6, 2014. DOI: 10.1001/jamainternmed.2014.3996
Medical Xpress on facebook
Related Stories
Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis
May 21, 2012
Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on ...
Outcomes for older adults with pneumonia who receive treatment including azithromycin
Jun 03, 2014
In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly ...
Moxifloxacin monotherapy equivalent to antibiotic combo
Jan 30, 2013
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer ...
New hypothyroidism treatment guidelines from American Thyroid Association
Sep 30, 2014
Levothyroxine (L-T4), long the standard of care for treating hypothyroidism, is effective in most patients, but some individuals do not regain optimal health on L-T4 monotherapy. New knowledge about thyroid ...
Protease inhibitor and NRTIs safe, effective in HIV treatment
Jul 19, 2014
(HealthDay)—An HIV treatment regimen of a boosted protease inhibitor (lopinavir) combined with nucleoside reverse-transcriptase inhibitors (NRTIs) is safe and effective in low-resource settings, according ...
Recommended for you
Controlling Ebola in communities is critical factor in containing outbreaks
6 hours ago
Reducing community transmission and changing behaviour in communities is key to containing Ebola outbreaks, according to new research into the first known outbreak of the virus in 1976 by researchers at the ...
More Ebola screening possible for United States
7 hours ago
Federal health officials said Monday the U.S. is weighing whether to institute extra screening at U.S. airports where travelers from Ebola-stricken African nations may be arriving, ahead of a White House ...
Uganda confirms Marburg fever recently killed man
9 hours ago
A Ugandan health worker recently died of Marburg, a highly infectious disease that manifests as a viral hemorrhagic fever, Uganda's Ministry of Health confirmed Monday as health workers moved to quarantine a total of 80 people ...
Fear grows in US following first diagnosed Ebola case
11 hours ago
Assurances from US health officials that there is almost no chance of a US Ebola outbreak are doing little to allay Americans' fears, days after the first domestic case was diagnosed.
Federal officials cast doubt on Ebola travel ban
12 hours ago
Top government health officials say they are opposed to placing a ban on travelers from Ebola-infected countries, warning that shutting down borders could impede efforts by aid workers to stop the spread ...
US doctor cleared of Ebola virus
13 hours ago
US health officials said that a doctor who returned to a hospital after being treated for the Ebola virus last month did not in fact have a new case of the infectious disease.
User comments
© Medical Xpress 2011-2014, Science X network
In a randomized clinical trial of antibiotic treatments for community-acquired pneumonia (CAP), researchers did not find that monotherapy with β-lactam alone was worse than a combination therapy with a macrolide in patients hospitalized with moderately severe pneumonia, write author Nicolas Garin, M.D., Hôpital Riviera-Chablais, Switzerland, and colleagues.
CAP is responsible for a high burden of deaths, hospitalizations and health care costs. International medical societies differ in their recommendations on how to treat it. North American guidelines recommend treatment of atypical pathogens with respiratory antibiotics or with a combination of a macrolide and a β-lactam for all hospitalized patients. European guidelines recommend combination therapy only for more severely ill patients. The authors sought to determine whether monotherapy with β-lactam alone was noninferior (not worse than) to a combination therapy with a macrolide for patients in the hospital with moderately severe pneumonia.
The randomized trial included 580 patients (291 received monotherapy and 289 had combination therapy). The median age of patients was 76 years.
After seven days of treatment, 120 of 291 patients (41.2 percent) who received monotherapy vs. 97 of 289 (33.6 percent) who had combination therapy had not reached clinical stability. Patients who were infected with atypical pathogens or with more severe pneumonia were less likely to reach clinical stability with monotherapy. Patients not infected with atypical pathogens or with less severity of illness had equivalent outcomes in the two treatment groups. There were more 30-day readmissions in the monotherapy treatment group (7.9 percent vs. 3.1 percent). Mortality, admission to the intensive care unit, complications, length of stay and pneumonia recurrence did not differ between the two groups within 90 days.
"We were unable to demonstrate noninferiority of initial empirical treatment with a β-lactam agent alone in hospitalized patients with moderately severe community-acquired pneumonia. There was a nonsignificant trend toward superiority of combination therapy, which could represent a chance finding or true superiority that was not significant because of insufficient power."
In a related commentary, Jonathan S. Lee, M.D., and Michael J. Fine, M.D., M.Sc., of the University of Pittsburgh School of Medicine, write: "We believe that evidence from this trial pushes the pendulum further in favor of antibiotic therapy covering atypical and typical bacterial pathogens for patients hospitalized for CAP. Lessons learned from its design and results should inform future trials required to definitively settle this debate. ... Finally, to maximize the detection of atypical pathogens and ensure their timely treatment in all study arms, future trials should use the most comprehensive point-of-care diagnostic testing for pneumonia pathogens. Although trials with these features would bring us substantially closer to ending the debate, until that time, dual therapy should remain the recommended treatment for patients hospitalized for CAP. "
Explore further: Outcomes for older adults with pneumonia who receive treatment including azithromycin
More information: JAMA Intern Med. Published online October 6, 2014. DOI: 10.1001/jamainternmed.2014.4887
Commentary: Debate on Antibiotic Therapy for Patients Hospitalized for Pneumonia, JAMA Intern Med. Published online October 6, 2014. DOI: 10.1001/jamainternmed.2014.3996
Medical Xpress on facebook
Related Stories
Combination antibiotic treatment does not result in less organ failure in adults with severe sepsis
May 21, 2012
Frank M. Brunkhorst, M.D., of Friedrich-Schiller University, Jena, Germany, and colleagues conducted a study to compare the effect of the antibiotics moxifloxacin and meropenem with the effect of meropenem monotherapy on ...
Outcomes for older adults with pneumonia who receive treatment including azithromycin
Jun 03, 2014
In a study that included nearly 65,000 older patients hospitalized with pneumonia, treatment that included azithromycin compared with other antibiotics was associated with a significantly lower risk of death and a slightly ...
Moxifloxacin monotherapy equivalent to antibiotic combo
Jan 30, 2013
(HealthDay)—Oral monotherapy with moxifloxacin is as efficacious and safe as combination therapy with ciprofloxacin plus amoxicillin/clavulanic acid for treatment of fever in adult patients with cancer ...
New hypothyroidism treatment guidelines from American Thyroid Association
Sep 30, 2014
Levothyroxine (L-T4), long the standard of care for treating hypothyroidism, is effective in most patients, but some individuals do not regain optimal health on L-T4 monotherapy. New knowledge about thyroid ...
Protease inhibitor and NRTIs safe, effective in HIV treatment
Jul 19, 2014
(HealthDay)—An HIV treatment regimen of a boosted protease inhibitor (lopinavir) combined with nucleoside reverse-transcriptase inhibitors (NRTIs) is safe and effective in low-resource settings, according ...
Recommended for you
Controlling Ebola in communities is critical factor in containing outbreaks
6 hours ago
Reducing community transmission and changing behaviour in communities is key to containing Ebola outbreaks, according to new research into the first known outbreak of the virus in 1976 by researchers at the ...
More Ebola screening possible for United States
7 hours ago
Federal health officials said Monday the U.S. is weighing whether to institute extra screening at U.S. airports where travelers from Ebola-stricken African nations may be arriving, ahead of a White House ...
Uganda confirms Marburg fever recently killed man
9 hours ago
A Ugandan health worker recently died of Marburg, a highly infectious disease that manifests as a viral hemorrhagic fever, Uganda's Ministry of Health confirmed Monday as health workers moved to quarantine a total of 80 people ...
Fear grows in US following first diagnosed Ebola case
11 hours ago
Assurances from US health officials that there is almost no chance of a US Ebola outbreak are doing little to allay Americans' fears, days after the first domestic case was diagnosed.
Federal officials cast doubt on Ebola travel ban
12 hours ago
Top government health officials say they are opposed to placing a ban on travelers from Ebola-infected countries, warning that shutting down borders could impede efforts by aid workers to stop the spread ...
US doctor cleared of Ebola virus
13 hours ago
US health officials said that a doctor who returned to a hospital after being treated for the Ebola virus last month did not in fact have a new case of the infectious disease.
User comments
© Medical Xpress 2011-2014, Science X network
0 comments:
Post a Comment